WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

New Drug Reference Application to Enable Access to Multilex DDF on the Move

Details
Research
17 April 2008
Healthcare professionals will soon be able to access the UK's leading drug knowledge base, the Multilex Drug Data File (Multilex DDF), on the move, following the development of a new drug reference application for mobile devices. First DataBank Europe (FDBE), working in partnership with Swedish software company MedHand International AB, will be offering the ability to browse Multilex DDF via a mobile device.
Read more ...

New DNA sequencing strategy could be vital during disease outbreak

Details
Research
15 April 2008
EU-funded scientists have developed a strategy to rapidly identify the genetic properties of virulent strains of bacteria. Such techniques will be essential in responding effectively to an epidemic of a new strain of a disease or a bioterrorist attack.
Read more ...

Latest Internet Technology for the Replacement of Animal Experiments

Details
Research
14 April 2008
Developed in close cooperation between Transinsight, Dresden, and the German Federal Institute for Risk Assessment, Berlin, the knowledge-based semantic search engine www.Go3R.org is now available online. It enables information transparency for the prevention of animal testing.
Read more ...

New light on how a mutation in a protein causes acute myeloid leukaemia

Details
Research
09 April 2008
An international team of scientists has shed new light on how a mutation in a protein causes acute myeloid leukaemia (AML), a type of blood cancer. The findings have implications for our understanding of AML, and the way leukaemias are treated. The work, which is partly funded by the EU, is published in the latest edition of the journal Cancer Cell.
Read more ...

Man-made chemicals which mimic oestrogen contribute to breast cancer

Details
Research
04 April 2008
Health campaigners are urging politicians to act on the growing body of scientific evidence that links exposure to certain chemicals to spiralling rates of breast cancer. Scientists have known for decades that a woman's risk of developing breast cancer is influenced both by the levels of oestrogen produced by her own body and her use of drugs containing man-made oestrogens, such as hormone replacement therapy (HRT).
Read more ...

Protein discovery sheds light on autoimmune diseases

Details
Research
03 April 2008
The immune system is made up of a collection of mechanisms that protect our bodies from disease and infection. But if you have an autoimmune disease, your own immune system attacks itself by mistake. Many parts of the body can be affected by these diseases, including nerves, muscles, and the endocrine and digestive systems.
Read more ...

Ascribe Extends Integrated Pharmacy and Robotic IT Systems to Royal Bolton Hospital

Details
Research
02 April 2008
Ascribe plc (AIM:ASP), the innovative health IT Group, today announced that it has successfully installed its Web Pharmacy solution at the Royal Bolton Hospital, part of the Bolton Hospitals NHS Trust and that the site is completely operational. One unique aspect of this 'Go Live' was that, on the same day that the hospital changed its pharmacy IT system, they also brought online a robotic dispensing system; thereby taking a massive leap forward in improving patient care and safety.
Read more ...

More Pharma News ...

  1. Female sex hormone helps protect against hearing loss
  2. The Drug Check eTEN Project to validate an on-line pan-European service
  3. Ozmosis - Trusted Environment for Physicians
  4. Doctors & Dentists Urged To Learn On The Net
  5. New EU project to focus on membrane proteins with the aim of finding new treatments
  6. Integrating sex and gender differences in health research
  7. Public consultation in preparation of a legal proposal to combat counterfeit medicines for human use
  • Start
  • Prev
  • 298
  • 299
  • 300
  • 301
  • 302
  • 303
  • 304
  • 305
  • 306
  • 307
  • Next
  • End
Tahmeena

Business & Industry

  • Pfizer reports record full-year 2022 results
  • AMJEVITA™ (adalimumab-atto), first biosimilar to Humira® now available in the United States
  • CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer
  • Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
  • Pfizer expands 'An Accord for a Healthier World' product offering to include full portfolio for greater benefit to 1.2 billion people in 45 lower-income countries

Research & Development

  • Scientists pinpoint protein that helps cancer-causing viruses evade immune response
  • Transforming the way cancer vaccines are designed and made
  • Antidepressants used for chronic pain on the rise, but are they effective?
  • Keys to making immunotherapy work against pancreatic cancer found in tumor microenvironment
  • Discovery of anti-cancer chemistry makes skullcap fit for modern medicine
  • Coordination of COVID-19 vaccine clinical trials produces a 'treasure trove' of data and a model for the future
  • Power of cancer drugs may see boost by targeting newly ID'd pathway

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  • FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
  1. You are here:  
  2. Home
  3. Research

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.